Pharmacologic Management of Obesity

These flashcards cover key vocabulary and concepts related to the pharmacologic management of obesity.

Obesity

Defined as a body mass index (BMI) ≥ 30 kg/m², or ≥ 27 kg/m² with comorbidities.

Pharmacotherapy

Medical treatment using medications to manage weight and obesity.

AOMs (Anti-Obesity Medications)

FDA-approved medications for long-term weight management.

GLP-1 Receptor Agonists

A class of drugs that mimic GLP-1 hormone to increase satiety and reduce appetite.

BMI (Body Mass Index)

A measurement to categorize weight status based on height and weight.

Sympathomimetic Agents

Medications that stimulate the sympathetic nervous system, used for appetite suppression.

Orlistat

A lipase inhibitor that reduces fat absorption by about 30%.

Naltrexone/Bupropion ER

A medication combination that modulates reward circuits and appetite.

Off-label Medications

Medicines used for weight loss without an FDA formal indication for obesity.

Phentermine

A sympathomimetic agent approved for short-term use to suppress appetite.

Topiramate

An anticonvulsant used off-label for modest weight loss, possibly via appetite suppression.

Contraindications

Conditions that make a particular drug or treatment inadvisable.

Adverse Effects

Unintended and harmful outcomes resulting from medication use.

Lifestyle Modification

Changes in diet, physical activity, and behavior to support weight loss.

Monitoring Parameters

Key indicators to assess safety and efficacy of weight-loss pharmacotherapy.

Efficacy

The ability to produce a desired or intended result, particularly in medication outcomes.